Healthcare & Life Sciences

Persson 1993 Background Material Submission FDA Docket

FDA has received and placed in docket FDA-2026-P-3869 background material titled 'Persson 1993' for public access. The document contains copyrighted content that is restricted from public viewing. This appears to be historical scientific literature submitted as supporting material in an FDA regulatory proceeding. No new regulatory requirements, deadlines, or compliance obligations are established by this docket filing.

Hellwig 2016 Background Material - FDA Docket FDA-2026-P-3869

FDA received background material originally prepared in 2016 and filed in docket FDA-2026-P-3869. The document appears to be supporting documentation associated with an FDA petition. No new regulatory requirements or compliance obligations are established by this filing.

Klaus 1982 FDA Document

FDA received a document submission dated April 15, 1982, from Klaus. The document content is restricted due to copyright and is not publicly accessible through regulations.gov. The submission is catalogued under docket FDA-2026-P-3869-0005. Specific regulatory content cannot be determined from the available metadata.

Peragallo 2018 Supporting Material FDA-2026-P-3869

FDA received supporting materials for Citizen Petition FDA-2026-P-3869 submitted by Peragallo. The document consists of 2018 supporting material referenced in the petition but the content is restricted due to copyright. The petition and supporting documentation were filed in the public docket for regulatory review.

Raglan 2019 Supporting Material

FDA received supporting material dated April 15, 2019, associated with submission FDA-2026-P-3869. The document content is restricted due to copyright. No specific regulatory requirements, deadlines, or penalties are stated in the visible portion of the document.

Piovani 2019 Supplemental Tables Supporting FDA Petition

FDA received supplemental tables (Piovani 2019) as supporting material filed under docket FDA-2026-P-3869. The document contains scientific data tables submitted to support a petition or submission before the agency. Affected parties should monitor this docket for related FDA actions or correspondence.

Konkle 2012 Background Material - FDA-2026-P-3869

FDA has received and posted background material (Konkle 2012) as part of docket FDA-2026-P-3869. The document content is restricted due to copyright and is not publicly accessible. The filing represents supporting documentation submitted to the FDA docket for regulatory review.

Ghajarzadeh 2022 Background Material for FDA Petition

FDA received background material from Ghajarzadeh dated 2022 as part of petition FDA-2026-P-3869. The submission consists of supporting documentation for a petition requesting FDA to take a specific regulatory action. The document was filed in the FDA regulations.gov docket system. No specific petition request, compliance obligations, or deadlines are stated in the available metadata.

Chen 2017 Background Material, FDA-2026-P-3869, Apr 3

Chen 2017 Background Material, FDA-2026-P-3869, Apr 3

FDA READI-Home Innovation Challenge for Medical Device Technologies

The FDA's Center for Devices and Radiological Health (CDRH) launched the Reducing Readmissions through Device Innovation for the Home (READI-Home) Innovation Challenge on April 7, 2026. The challenge invites medical device innovators to develop home-based technologies that support patients and caregivers following acute hospital stays and help prevent readmissions. Submissions must meet the FD&C Act device definition and address unmet home healthcare needs.

CDC Agency Forms Undergo Paperwork Reduction Act Review

CDC published a notice announcing that certain agency forms are undergoing the Paperwork Reduction Act review process. The notice identifies forms under review by docket number 30Day-26-1335 and invites public comment on these information collections. Affected parties who submit information to CDC using these forms may wish to monitor the review for any changes to reporting requirements.

CDC Proposes Data Collection Under Paperwork Reduction Act

The CDC has published a notice proposing a new data collection under the Paperwork Reduction Act. The notice requests public comments on the proposed collection of information. The comment period closes 61 days from the date of publication.

CDC Proposes Data Collection Under Paperwork Reduction Act

CDC proposes a new data collection under the Paperwork Reduction Act and seeks public comments. The notice requests feedback on the proposed data collection, associated burden estimates, and collection methods. Comments are due June 15, 2026.

Call for Nominations for Center for Indigenous Innovation and Health Tribal Advisory Committee

The HHS Office on Minority Health (OMH) is accepting nominations for primary and alternate delegates to serve on the Center for Indigenous Innovation and Health Tribal Advisory Committee (CIIH TAC). The CIIH TAC provides tribal leaders a forum to exchange views and provide feedback on activities addressing four priority areas: research, education, service, and policy development. Nomination letters must be submitted by May 18, 2026.

Advisory Council on Alzheimer's Research, Care, and Services Meeting

HHS announces a public meeting of the Advisory Council on Alzheimer's Research, Care, and Services scheduled for Monday, April 27, 2026, from 1:00 p.m. to 5:00 p.m. The meeting is open to the public for attendance and comment participation. This is a routine advisory council meeting announcement with no new compliance obligations.

CMS Schedules June 2026 Public Meeting on HCPCS Level II Code Revisions

CMS announces the first biannual 2026 public meeting for HCPCS Level II coding to discuss preliminary coding, Medicare benefit category, and payment determinations for new non-drug and non-biological items and services. The primary meeting is scheduled for June 1, 2026, in Baltimore with a virtual overflow option on June 2, 2026. Speaker registration and in-person attendance requests are due by May 18, 2026, and written comments may be submitted until June 3, 2026.

FDA Oversight of Compounded GLP-1 Drugs, Active

HHS OIG announced an active study to assess FDA's oversight of compounded glucagon-like peptide-1 receptor agonist (GLP-1) drugs. The study will examine FDA's inspection of compounding facilities and use of available data to identify and address potential risks to patients. GLP-1 drugs were on FDA's drug shortage list from 2022 to 2025, during which compounding facilities were permitted to produce copies. The study is estimated for completion in fiscal year 2028.

NIH Recipients' Oversight of Domestic Subrecipients

HHS OIG announced a new evaluation (OEI-04-26-00170) to assess NIH prime recipients' adherence to requirements for oversight of domestic subrecipients under the NIH Grants Policy Statement and OMB Uniform Guidance. The evaluation aims to reduce fraud, waste, and abuse in domestic NIH subawards, with an estimated completion date of FY2028.

TANF Cash Assistance Program Oversight Audit Series Announced

HHS OIG announced a new audit series (SRS-A-26-017) to examine state oversight of the Temporary Assistance for Needy Families (TANF) program, which distributes $16.6 billion annually in federal block grant funds to states. The audits will focus on whether states provided adequate oversight of TANF cash assistance programs, including the use of electronic benefit transfer (EBT) cards. One project (OAS-26-09-021) has been announced with an estimated completion in FY2028.

IDOH Vital Records LHD Webinar

The Indiana Department of Health has scheduled a virtual webinar on vital records for Local Health Department staff on April 16, 2026 from 10:00am to 11:00am EDT. The event is hosted by IDOH's LHD Program and appears to be an informational training session. No regulatory requirements, compliance obligations, or new policies are being established through this event.

Delaware Healthy Mother & Infant Consortium Celebrates 20th Anniversary During Annual Summit

The Delaware Healthy Mother & Infant Consortium marked its 20th anniversary at its annual summit with a keynote address by Multi-Emmy Award-winning director Emmai Alaquiva. Alaquiva discussed his award-winning film The Ebony Canal and addressed maternal health disparities affecting Black and Brown communities. The event celebrated the consortium's two decades of work on infant outcomes in Delaware.

USPTO Patent US12601742B2 for Endometrial Cancer Treatment Methods

USPTO granted patent US12601742B2 to Mayo Foundation for Medical Education and Research covering methods and materials for assessing and treating endometrial cancer. The patent covers methods for identifying endometrial cancers likely to respond to particular cancer treatments by assessing combinations of mutations and expression levels, such as platinum-based therapies. The patent contains 22 claims.

Cancer Vaccine Patent hESCs TLR3 Adjuvant Assigned to INSERM

USPTO granted patent US12599662B2 to INSERM for a cancer vaccine composition using irradiated human embryonic stem cells combined with a TLR3 adjuvant. The patent covers methods for treating cancers including breast cancer by inducing MHC-I presentation of antigens. The patent includes 16 claims.

Sudan Crisis, 4M Malnourished, 37% Health Facilities Closed

WHO reports that three years of conflict in Sudan have created the world's largest humanitarian and displacement crisis. Nearly 4 million people are estimated to be acutely malnourished in 2026, with disease outbreaks including malaria, dengue, measles, and polio spreading across multiple states. Some 37% of health facilities across Sudan's 18 states remain non-functional, while WHO has verified 217 attacks on health care since April 2023.

Safety Assessment of Genome Editing Human Gene Therapy Products Using Next-Generation Sequencing

FDA's Center for Biologics Evaluation and Research has issued draft guidance recommending next-generation sequencing (NGS)-based methods for assessing safety of human genome editing gene therapy products in nonclinical studies. The guidance addresses evaluation of off-target editing risks and genome integrity for products supporting IND and BLA applications. Comments are being accepted via regulations.gov under docket FDA-2026-D-1255.

STI Awareness Week: Talk, Test, Treat

MSDH announces STI Awareness Week (April 12-18) and releases 2025 STI trend data. Reported changes include: 2.4% increase in chlamydia, 0.6% decrease in gonorrhea, 21.9% decrease in syphilis, 48% decrease in congenital syphilis, and 4.9% decrease in HIV. The department promotes Talk, Test, Treat messaging and provides information on free testing, PrEP, and condom distribution at county health clinics.

Tribal Consultation Meeting HHS/ACF OHS Head Start Programs

HHS/ACF OHS announces a Tribal Consultation session on June 18, 2026, to meet with tribal government leaders operating Head Start and Early Head Start programs. The consultation will address funding allocations, distribution formulas, and service delivery for American Indian and Alaska Native children and families. A report will be published within 45 days of the meeting.

Center for Scientific Review Notice of Closed Meetings

The NIH Center for Scientific Review announces five closed meetings scheduled for May 8, 2026. Review panels will evaluate grant applications in oncological sciences, medical informatics, genetics, endocrinology, and career development awards. Meetings are closed pursuant to the Federal Advisory Committee Act due to confidential grant information.

Center for Scientific Review Notice of Closed Meetings

The National Institutes of Health Center for Scientific Review announces five closed meetings scheduled for May 12-13, 2026. The meetings will review and evaluate grant applications for clinical vision research, reproductive/perinatal/pediatric health, contraceptive development, immunity/host defense, and aging tissue research. Meetings are closed under provisions of the Federal Advisory Committee Act because discussions could disclose confidential trade secrets, commercial property such as patentable material, and personal information of individuals associated with grant applications.

Financial Transparency and Efficiency of PDUFA, BsUFA, and GDUFA; Public Meeting

The FDA is announcing a public meeting on June 23, 2026, to discuss financial transparency and efficiency of the Prescription Drug User Fee Act (PDUFA), Biosimilar User Fee Act (BsUFA), and Generic Drug User Fee Amendments (GDUFA). The hybrid meeting will be held at FDA White Oak Campus and via Microsoft Teams. Written and electronic comments on the meeting topic must be submitted by July 23, 2026.

Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry

FDA announced availability of draft guidance providing recommendations for next-generation sequencing (NGS)-based methods used in nonclinical studies to support initiation of clinical trials of investigational human genome editing products. The draft guidance is open for public comment until July 14, 2026 (90-day comment period). Comments should be submitted to Docket No. FDA-2026-D-1255.

Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments

The FDA announced a public meeting on April 23, 2026 to gather stakeholder perspectives on increasing access to nonprescription drugs. The meeting will be held virtually and in person at the National Press Club in Washington, DC. Written and electronic comments are due by May 8, 2026.

Peptide Amide Composition for Kappa Opioid Receptor Treatment

USPTO granted Patent US12599647B2 to Xizang Haisco Pharmaceutical Co., Ltd. for a peptide amide composition containing a compound of formula (I) and pH regulators (pH 3-5.5). The composition is designed for treating or preventing diseases or conditions associated with kappa opioid receptors. The patent includes 19 claims and covers the compound composition, preparation methods, and medical applications.

Nestlé Granted Patent for Green Coffee Insulin Treatment Composition

USPTO granted Patent US12599643B2 to Societe des Produits Nestle S.A. for green coffee-based compositions comprising hydrolysed chlorogenic acid for improving insulin profile. The patent covers compositions for treating or preventing disorders linked to increased plasma postprandial insulin, including esterase treated decaffeinated green coffee extract with 40-200 mg daily dosage. The patent contains 16 claims and was filed March 27, 2020.

Free Soil Testing Events Hot Springs April 22-25

The Arkansas Department of Health announces free soilSHOP events in Hot Springs on April 22-25, 2026. Partnering with Master Gardeners of Garland County, Child Care Aware, National Park College, ATSDR, and EPA Region 6, the events will offer free lead screening of soil samples and health education on environmental hazards. Up to three soil samples per person may be submitted for testing.

CyPep-1 Peptide Composition for Treating Neoplastic Lesions

USPTO granted patent US12599646B2 to CYTOVATION ASA covering a pharmaceutical composition comprising therapeutic peptide CyPep-1 for treating neoplastic lesions, particularly warts. The patent, with 16 claims, was filed on March 10, 2020, and includes CPC classifications related to peptide formulations and therapeutic applications.

Thrombolytic Agents for Intravascular Clots - US12599653B2

The USPTO granted Patent US12599653B2 to Jinis Co., Ltd. for a thrombolytic agent comprising a dual-domain polypeptide with a thrombo-recognition domain and a thrombolytic domain effective for dissolving intravascular thrombus. The patent covers a pharmaceutical composition designed to prevent and treat thrombosis with reduced bleeding side effects compared to conventional thrombolytic therapies. The patent application was filed October 19, 2020, under Application No. 17770795.

Acellular Amniotic Fluid for Ischemic Injury Treatment

USPTO granted patent US12599635B2 to University of Utah Research Foundation covering compositions and methods for treating ischemic injuries using acellular amniotic fluid (acAF). The patent names inventors Hadi Javan, Craig H. Selzman, Young Sook Lee, Jo-Anna Reems, and Jan L. Pierce, and includes 31 claims. The patent application was filed March 22, 2021 under application number 17912730.

Cytotoxic Imidazopyridine Compounds and Their Use in Therapy

The USPTO granted Patent US12599676B2 to MyricX Pharma Limited for cytotoxic imidazo[1,2-A]pyridine compounds and their therapeutic use. The patent covers compounds of formula (I) classified under A61P 35/00 for cancer therapy. The application (19072750) was filed March 6, 2025, and the patent contains 23 claims.

Demethylating Agent Melanoma Treatment Method Using STING Signaling Enhancement

USPTO granted patent US12599621B2 to H. Lee Moffitt Cancer Center covering methods for enhancing anti-tumor T cell responses in melanoma subjects with defective STING signaling using demethylating agents. The patent, filed January 21, 2021, includes claims to methods of treatment involving demethylating agents, STING agonists, and tumor infiltrating lymphocytes. Inventors: James Mulé, Rana Falahat, Glen Barber.

Integrin α10-Selected MSCs Treat Skin Defects

USPTO granted patent US12599633B2 to Xintela AB covering integrin α10-selected mesenchymal stem cell compositions for treating skin defects, with 20 claims. The patent protects cell populations and culture conditions that enhance viability and regenerative function in wound healing applications.

US12599620B2 - Chronic Fatigue Syndrome Plasma Cell Inhibitor Treatment Method

The USPTO granted Patent US12599620B2 to Vestlandets Innovasjonsselskap AS covering a method for treating chronic fatigue syndrome using inhibitory or cytotoxic agents against plasma cells. The patent also claims combinations of plasma cell-targeting agents with B-cell depleting agents or B-cell activation inhibitors. The patent application was filed on August 31, 2020, under application number 17638453, and contains 3 claims.

SIRPγ Inhibitor for Cancer Treatment | US12599650B2

USPTO granted patent US12599650B2 to AMGEN INC. covering methods of treating tumors or cancer using SIRPγ inhibitors. The patent, invented by Ruozhen Hu, Paolo Manzanillo, and Wenjun Ouyang, contains 9 claims. Filing date was June 23, 2020 (Application No. 17618922).

Pharmaceuticals and Dosing Means for Human Aging Reversal

The USPTO granted patent US12599651B2 to Intervene Immune Inc. on April 14, 2026. The patent covers pharmaceutical compositions combining human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin for reversing age-related changes including systemic inflammation, cancer risk, thymus function, immune cell populations, and epigenetic age. The patent contains 11 claims.

MaxCyte Electroporation Device Design Patent USD1122471S1

The USPTO granted Design Patent USD1122471S1 to MaxCyte, Inc. for an electroporation device design. The patent application was filed on March 5, 2025, with inventors James William Luther, Bertold Engler, Andrea Besana, and Thomas Alan Peach. One design claim was granted. Design patents protect the ornamental appearance of a functional item for a term of 15 years from grant date.

EMS Training Committee to Meet Thursday, Apr. 16, 2026

The South Carolina Department of Public Health announces that the EMS Training Committee will meet on Thursday, April 16, 2026 at 10 a.m. at the State of South Carolina Health Campus, Conference Room A141, 400 Otarre Parkway, Cayce. The meeting is open to the public and the agenda and virtual viewing link are available on the meeting event page.

Kyprolis Visible Particles After Reconstitution - Safety Communication

Swissmedic issued a health professional communication regarding Kyprolis (carfilzomibum) 10 mg and 60 mg following routine stability monitoring that detected visible particles (transparent, colorless) in reconstituted samples. All distributed batches remain safe for use. The communication emphasizes strict adherence to visual inspection procedures per approved reconstitution instructions before administration.

Draeger Atlan A350 and A350 XL Anesthesia Workstation Correction

FDA classified Draeger Atlan A350 and A350 XL anesthesia workstations as a Class I recall—the most serious type—due to potential piston ventilator failure before or during use. Draeger is instructing customers to inspect and, if necessary, replace the ventilator motor assembly. Healthcare providers may continue using affected devices under permanent supervision until the corrective action is implemented.

Standard Textile Incontinence Pad Patterned Surface

USPTO granted Design Patent USD1122441S1 to Standard Textile Co., Inc. for an incontinence pad with patterned surface design. The patent has 1 claim under application number 29877572 filed June 8, 2023. Competitors in the incontinence or hygiene product market should review this design patent for potential ornamental design overlap.

Window Handcrank Manipulator Design Patent USD1122478S1

USPTO granted design patent USD1122478S1 for a Window Handcrank Manipulator invented by Robert Fritz. The patent was issued April 14, 2026, with Application No. 29929345 filed February 21, 2024. The design patent contains 1 claim and covers a mechanical device design used for operating window cranks.